自体与异基因造血干细胞移植后接种蜱传脑炎疫苗的免疫应答与安全性
本研究评估了104例白血病、骨髓瘤和淋巴瘤患者在接受自体或异基因造血干细胞移植后接种4剂蜱传脑炎疫苗的应答与副作用。移植后9、10、12和21个月接种FSME-Immun®疫苗,异基因和自体移植后血清抗体阳性率分别为77%和80%,IgG水平分别为89 vs 94 U/mL;持续慢性GVHD和免疫抑制与末次样本血清阴性相关(p=0.007)。结论认为移植后9个月起接种4剂疫苗是安全的,且绝大多数患者可诱导血清阳性。
要点
- 移植后9个月起接种4剂TBE疫苗,异基因和自体移植后血清阳性率分别为77%和80%。
- 持续慢性GVHD和免疫抑制与末次样本血清阴性相关(p=0.007)。
- 所有健康对照(n=27)接种3剂后均产生保护性抗体水平。
核心结论
- 移植后9个月起接种4剂蜱传脑炎疫苗是安全的,且绝大多数患者可诱导血清阳性。
研究设计与样本
- 纳入104例白血病、骨髓瘤和淋巴瘤患者,中位年龄61岁,在移植后9、10、12和21个月接种FSME-Immun®疫苗,接种前后采集血清。
- 健康对照27例接种3剂疫苗。
- 采用Enzygnost anti-TBE ELISA检测TBE特异性IgG抗体。
主要发现
- 异基因和自体干细胞移植后抗体水平(>12 U/mL,即血清阳性)分别见于77%和80%的患者。
- 异基因与自体移植后IgG水平分别为89 vs 94 U/mL。
- 持续慢性GVHD和免疫抑制(n=29)与末次样本血清阴性相关(p=0.007)。
- 所有对照(n=27)均产生保护性抗体水平。
关键数值与推荐
- 血清阳性定义为TBE特异性IgG抗体>12 U/mL。
- 移植后9、10、12和21个月共接种4剂FSME-Immun®疫苗。
- 健康对照接种3剂疫苗。
临床怎么用
- 对自体或异基因造血干细胞移植患者,可考虑在移植后9个月开始接种4剂蜱传脑炎疫苗。
- 对合并持续慢性GVHD和免疫抑制的患者,接种后应关注血清阴性可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Our aim was to assess response and side effects of 4 doses of TBE vaccine to patients (pts) after allo- and autologous stem cell transplantation (SCT). PATIENTS: Included were 104 pts with leukaemia, myeloma and lymphoma, median age 61 yrs. METHODS: Vaccine (FSME-Immun®) was given at 9, 10, 12, and 21 months post-transplant. Serum samples were obtained before and after vaccinations. Healthy controls (n = 27) received 3 vaccinations. Assessments of TBE specific IgG antibodies were performed by Enzygnost anti-TBE ELISA test (Siemens, Sweden). RESULTS: Antibody levels (>12 U/mL; "seropositivity") were seen in 77% and 80% of pts after allo- and autoSCT; IgG levels; 89 vs 94 U/mL. Ongoing chronic GvHD and immunosuppression (n = 29) was associated with sero-negativity in the last sample (p = 0.007). All controls (n = 27) developed protective antibody levels. CONCLUSIONS: TBE vaccination was safe, and 4 doses starting 9 months post-SCT, induced seropositivity in a vast majority of pts.
引用
- Einarsdottir S, Nicklasson M, Veje M, et al. Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation. Vaccine. 2021. PMID: 33483213. doi:10.1016/j.vaccine.2020.12.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。